The DEA's June 29 Hearing Could Change Cannabis Forever—Here's What's at Stake

In less than four weeks, at a federal building at 700 Army Navy Drive in Arlington, Virginia, something will happen that cannabis advocates have been fighting for since before most of today's consumers were born. The Drug Enforcement Administration will open a formal hearing to consider whether marijuana should be moved from Schedule I — the category reserved for substances with "no accepted medical use" and "high potential for abuse," alongside heroin and LSD — to Schedule III, where it would sit beside testosterone, Tylenol with codeine, and anabolic steroids.

The hearing is scheduled to run from June 29 through July 15, with a short recess from July 3 to July 6. It will examine, in the DEA's words, "factual evidence and expert opinion" regarding the reclassification of all marijuana products.

This is not a symbolic gesture. This is the most significant federal cannabis policy proceeding in nearly nine decades. And the outcome will ripple through every dispensary, every grow operation, every research lab, and every living room where someone is quietly using cannabis to manage their pain, their anxiety, or their insomnia.

Let's break down what is actually happening, how we got here, and what it means for you.

The Road to 700 Army Navy Drive

The rescheduling conversation did not start this year or even last year. The Department of Health and Human Services formally recommended rescheduling marijuana in 2023, citing extensive scientific evidence that cannabis has accepted medical applications and does not meet the criteria for Schedule I classification. That recommendation was a bombshell — it was the first time a federal health agency had taken such a definitive position on the issue.

But federal bureaucracy does what federal bureaucracy does best: it moved slowly. The recommendation sat in the pipeline for over two years while the political landscape shifted underneath it.

Then came December 18, 2025, when President Trump signed an executive order directing federal agencies to expedite the rescheduling process. Whatever your politics, the executive order was a clear signal that the White House wanted this done.

The real acceleration came on April 23, 2026, when Acting Attorney General Todd Blanche issued an order that caught even close observers off guard. Blanche placed FDA-approved and state-licensed medical marijuana into Schedule III immediately and ordered an expedited hearing on broader rescheduling. That order effectively created a two-track system: approved medical marijuana is already Schedule III, while the question of reclassifying all marijuana products is what the June 29 hearing will address.

What Happens at the Hearing

Federal administrative hearings are not courtroom dramas. They are methodical, evidence-driven proceedings where experts present testimony, data is entered into the record, and interested parties make their case before an administrative law judge.

The DEA hearing will consider several fundamental questions. Does marijuana have accepted medical use? What is its actual abuse potential compared to other scheduled substances? What does the scientific literature say about its safety profile? These questions might seem absurd to anyone who has followed cannabis research over the past decade, but the legal process requires that they be formally addressed in the record.

Multiple stakeholders will be presenting testimony. Federal agencies, medical researchers, cannabis industry representatives, and advocacy groups will all have the opportunity to present evidence. The hearing will also likely hear from opponents of rescheduling — prohibitionist groups that have filed lawsuits attempting to block the entire process.

One organization fighting hard for a seat at the table is NORML, the National Organization for the Reform of Marijuana Laws. NORML has argued that consumers — the people who actually use cannabis — must be represented in these proceedings, not just researchers, regulators, and industry lobbyists. It is a fair point. When the federal government makes decisions about a substance used by tens of millions of Americans, the people most directly affected should have a voice.

The Opposition Is Not Going Quietly

Make no mistake: there are organized, well-funded groups that want this hearing to fail. Prohibitionist organizations have filed lawsuits seeking to stop the rescheduling process entirely. Their arguments range from procedural objections — claims that the process has been rushed or politicized — to substantive challenges asserting that marijuana does not meet the criteria for Schedule III.

These legal challenges are not frivolous, even if you disagree with their premise. Federal scheduling decisions are subject to judicial review, and courts have historically given significant deference to agencies on scientific determinations. But a well-crafted lawsuit could delay the process by months or even years, forcing the issue into the federal court system while the administrative process stalls.

This is the quiet danger that does not make headlines. Even if the hearing goes perfectly and the evidence overwhelmingly supports rescheduling, a single federal judge could issue an injunction that freezes the entire process. It has happened before in other regulatory contexts, and the prohibitionist groups know exactly which courts to file in.

What Schedule III Actually Means

There is a widespread misunderstanding about what rescheduling would and would not do. Let's be clear about what is on the table.

What Schedule III would change:

Moving marijuana to Schedule III would fundamentally alter the federal tax landscape for cannabis businesses. Under the current Schedule I classification, cannabis companies are subject to Section 280E of the Internal Revenue Code, which prevents them from deducting ordinary business expenses. This means cannabis companies pay effective tax rates that can exceed 70 percent — a crippling burden that has driven countless businesses into insolvency. Schedule III would eliminate the 280E problem, allowing cannabis companies to deduct expenses like any other business.

Rescheduling would also open the door to federal research on a scale that has been impossible under Schedule I. Universities, pharmaceutical companies, and independent labs would have dramatically easier access to cannabis for clinical trials and scientific studies. The research bottleneck that has kept us in the dark about cannabis for decades would finally begin to ease.

Schedule III classification would also reduce the banking challenges that have plagued the cannabis industry. While it would not automatically solve every banking issue, it would remove the primary legal justification that banks and credit unions have used to refuse service to cannabis businesses.

What Schedule III would NOT do:

Rescheduling to Schedule III is not legalization. Cannabis would still be a controlled substance under federal law. It would still require a prescription or state authorization for legal use. It would not automatically make recreational cannabis legal at the federal level.

State laws would remain the primary regulatory framework for cannabis, and the patchwork of state-by-state legalization would continue. Consumers in prohibition states would not suddenly gain access to legal cannabis because of a scheduling change.

It is also worth noting that Schedule III substances can still be subject to federal enforcement. While the practical likelihood of the DEA going after state-legal cannabis operations would decrease significantly, the legal authority would technically remain.

The Timeline Problem

Even under the most optimistic scenario, this process will take time. The hearing runs through July 15. After the hearing, the administrative law judge must review the record, evaluate the testimony, and issue findings. The DEA then has to consider those findings and issue a final rule. Public comment periods, review cycles, and the inevitable legal challenges add more time.

If everything moves smoothly — and in federal rulemaking, "smoothly" is a relative term — a final rule could arrive by late 2026. But legal challenges from prohibitionist groups could push the resolution into 2027 or beyond. The lawsuit already filed is not the last one we will see.

This timeline frustration is familiar to anyone who has followed cannabis policy. The gap between what the science says, what the public supports, and what the government does has been a defining feature of cannabis politics for decades. But the gap is narrower now than it has ever been.

Why This Hearing Matters More Than Any Before It

The cannabis policy landscape has seen plenty of "historic moments" that turned out to be false starts. Congressional hearings that went nowhere. Executive memos that were reversed by the next administration. Court decisions that settled nothing.

This one is different for several reasons.

First, the HHS recommendation provides a scientific foundation that is difficult to challenge. The federal government's own health agency has said, in writing, that marijuana does not belong in Schedule I. That is not an advocacy group's opinion or a politician's campaign promise — it is a formal determination by the agency responsible for evaluating drug safety.

Second, the executive order and AG Blanche's April directive demonstrate political will from the top. Previous rescheduling efforts stalled because no one in a position of authority was willing to push. That dynamic has changed.

Third, public opinion has made the political calculus unmistakable. Polls consistently show that over 70 percent of Americans support some form of cannabis legalization, and over 90 percent support medical marijuana specifically. A Johns Hopkins study earlier this year found that 92 percent of Americans support rescheduling. Politicians who oppose rescheduling are increasingly finding themselves on the wrong side of their own voters.

Fourth, the economic argument has become impossible to ignore. The legal cannabis industry generates billions in tax revenue, employs hundreds of thousands of workers, and supports ancillary businesses from real estate to technology. The economic cost of maintaining Schedule I classification — lost tax revenue, banking inefficiencies, business failures from 280E — is measured in the billions.

The Human Stakes

It is easy to get lost in the policy details and forget what this hearing is really about. Behind every scheduling decision, every regulatory proceeding, every legal challenge, there are real people whose lives hang in the balance.

There are cancer patients who rely on cannabis to manage the nausea from chemotherapy. There are veterans with PTSD who have found relief in cannabis after years of being prescribed opioids that nearly killed them. There are children with epilepsy whose seizures are controlled by cannabis-derived medications. There are elderly patients with chronic pain who chose cannabis over addictive painkillers.

And there are the millions of people — disproportionately Black and Latino — who have been arrested, prosecuted, and incarcerated for possessing a substance that the federal government's own health agency now says was misclassified. Schedule I classification did not just affect policy; it destroyed lives. Every day that marijuana remains in Schedule I is another day that the federal government maintains a classification that its own scientists have said is wrong.

What You Can Do

If you are reading this and thinking that none of this affects you, consider this: the outcome of the June 29 hearing will shape cannabis policy for a generation. Whether you are a medical patient, a recreational consumer, an industry professional, or simply someone who believes that government policy should be based on science rather than stigma, this hearing matters.

NORML and other advocacy organizations are actively seeking to ensure that consumer voices are included in the proceedings. Contact your elected representatives and tell them that rescheduling matters to you. Support organizations that are fighting for representation at the hearing. Stay informed about the process and push back against misinformation from prohibitionist groups.

The hearing at 700 Army Navy Drive begins on June 29. By the time it concludes on July 15, the administrative record will contain the most comprehensive federal examination of marijuana classification in American history.

What happens after that is up to the system — and to us.

The Bottom Line

We are closer to meaningful federal cannabis reform than at any point in modern American history. The science supports rescheduling. The public supports rescheduling. The executive branch supports rescheduling. The economic case for rescheduling is overwhelming.

But "closer" is not "there." Legal challenges, procedural delays, and political maneuvering could still slow or derail the process. The prohibitionist opposition is organized, funded, and determined. The federal bureaucracy is vast and slow.

June 29, 2026, is not the finish line. It is the starting gun for the final stretch. And after decades of waiting, the cannabis community cannot afford to look away now.